Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial...

Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure ... (more)

http://ift.tt/1idVWmU?